Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: A randomized, controlled trial

American Journal of Therapeutics

Volumn 13, Issue 3, 2006, Pages 229-235

  Alper Jr , Arnold B ^a   Tomlin, Holly ^a   Sadhwani, Usha ^a   Whelton, Andrew ^b   Puschett, Jules ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Universal Clinical Research Center Inc   (United States)

Author keywords

Acid base homeostasis; Carbonic anhydrase; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETAZOLAMIDE; AMLODIPINE; BENAZEPRIL; BICARBONATE; CARBONATE DEHYDRATASE; CELECOXIB; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; FELODIPINE; LISINOPRIL; LOSARTAN; NIFEDIPINE; PLACEBO; QUINAPRIL; SODIUM; TELMISARTAN; VERAPAMIL;

ACID BASE BALANCE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURESIS; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPERTENSION; IN VITRO STUDY; KIDNEY PROXIMAL TUBULE; MALE; METABOLIC ACIDOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SODIUM URINE LEVEL;

ACETAZOLAMIDE; ADULT; BICARBONATES; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CYCLOOXYGENASE INHIBITORS; FEMALE; HOMEOSTASIS; HUMANS; KIDNEY TUBULES, PROXIMAL; MALE; MIDDLE AGED; PYRAZOLES; SODIUM; SULFONAMIDES;

EID: 33745837444     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000182359.63457.01     Document Type: Article

References (20)

1. Bombardier C, Laine L, Reicin A, et al. comparison of upper intestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
3. Whelton A, Maurath CJ, Verburg KM, et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase inhibitor. Am J Ther. 2000;7:159-176.
4. Whelton A, Schulman G, Wallermark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med. 2000;160:1465-1470.
5. Whelton A, Fort JG, Puma JA, et al. SUCCESS VI Study Group. Cyclo-oxygenase-2-specific inhibitors and cardiorenal function: a randomized controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95.
6. Whelton A, White WB, Bello AE, et al. SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥ 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-963.
7. Celecoxib. FDA-NDA. 1998;20-998:1-225.
8. Bhagavan NV. Medical Biochemistry, 2nd ed. Boston: Jones and Bartlett Publishers; 1992:14-15.
9. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type II diabetes mellitus. Arch Intern Med. 2005;165:161-168.
10. Whelton A. The coxib conundrum: lessons from the rise and fall of rofecoxib [Editorial]. Am J Ther. 2004;11:417-471.
11. White WB, Faich G, Whelton A, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen and diclofenac. Am J Cardiol. 2002;89:425-430.
12. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med. 2001;100:335-125.
13. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-1711.
14. Mamdani M, Juurlink DN, Lee DS, et al. Cyclooxygenase-2-inhibitors versus non-selective non-steroidal anti-inflammatory drug and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751-1756.
15. Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacologic opportunities due to related binding site recognition. J Med Chem. 2004;47:550-557.
16. Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial dysfunction in salt-induced hypertension. Circulation. 2003;108:2308-2311.
17. Hermann M, Shaw S, Kiss E, et al. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension. 2005;45:193-197.
18. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-109.
19. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003;42:310-315.
20. Walter MF, Jacob RF, Day CA, et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004;177:235-243.